Clinical Trials

Inclusion Criteria:

• Histologically or cytologically confirmed multiple myeloma
• Prior treatment with or intolerance to proteasome inhibitor and immunomodulator
• Bone marrow biopsy within 28 days of study drug infusion demonstrating at least 5% plasma cell involvement
• Progressive disease defined by any of following: 25% increase in serum M-protein from lowest response value during (or after) last therapy and/or absolute increase in serum M-protein of > or equal to 0.5 g/dL; 25% increase in urine M-protein from lowest response value during (or after) last therapy and/or absolute increase in urine M-protein of > or equal to 200 mg/24h; 25% increase in bone marrow plasma cell percentage from lowest response value during (or after) last therapy - absolute bone marrow plasma cell percentage must be > or equal to 10% unless prior complete response when absolute bone marrow plasma cell percentage must be > or equal to 5%; new onset hypercalcemia > 11.5 mg/dL
• Measurable disease defined by any of following: Serum M-protein > 1 g/dL; Urine M-protein > 200 mg/24h; Serum free light chain (FLC) assay: involved FLC level > or equal to 10 mg/dL provided serum FLC ratio is abnormal; subjects who are non-secretors will be considered on a case-by-case basis
• Eastern Cooperative Oncology Group performance status of 0 to 2
• Life expectancy of at least 6 months
• Have initiative and means to be compliant with protocol and within geographical proximity to make required study visits as judged by Investigator
• Subject or legal representative has ability to read, understand and provide written informed consent for study related procedures
• Women of childbearing potential must have negative pregnancy test within 24 hours of enrollment
• Women of childbearing potential and men who are able to father a child, must agree to use an effective contraception method during study and for 12 months following study drug administration

Exclusion Criteria:

• Grade 2 or greater toxicities due to previous therapies, subject to laboratory abnormalities listed below. Stable, tolerable Grade 2 adverse events may be allowed at discretion of Investigator
• Prior external beam radiation therapy resulting in greater than 20% total bone marrow receiving greater than 20 Gy
• Prior radioisotope therapy
• Prior total body or hemi-body irradiation
• Extradural tumor in contact with the spinal cord or tumor located where swelling in response to therapy may impinge upon spinal cord
• Subject has any of following laboratory abnormalities: WBC < 3000/uL; ANC < 1500/uL; Hemoglobin < 8 g/dL; Estimated glomerular filtration rate < 30 mL/min/1.73 m2; ALT > 3 x ULN ; Bilirubin > 1.5 x ULN
• Platelet count < 100,000/uL without full-dose anticogulation therapy
• Platelet count < 150,000/uL with ongoing full-dose anticoagulation therapy
• Clinically significant bleeding event, as judged by investigator, within prior 6 months
• Chronic immunosuppressive therapy
• Anti-platelet therapy, except low-dose aspirin for cardioprotection
• PTT > 1.3 x ULN
• INR > 1.3
• Radiation therapy, chemotherapy, immunotherapy, investigational therapy or corticosteroid use within 2 weeks of or after eligibility-defining bone marrow biopsy. Bisphosphonates and denosumab are permitted if subject has been receiving for at least 90 days
• History of hypersensitivity to iodine
• Any other concomitant serious illness or organ system dysfunction in opinion of Investigator would either compromise subject safety or interfere with test drug safety evaluation
• Major surgery within 6 weeks of enrollment
• Known history of HIV, hepatitis C or hepatitis B infection
• Pregnancy or breast-feeding